David Grayzel
UnclaimedCurrent Firm
Atlas Venture
Focus
Biotech, Digital Health
About David Grayzel
David Grayzel is a physician-turned-venture capitalist at Atlas Venture who repeatedly co-founds and takes on CEO or chair roles at the biotech companies he backs, rather than staying purely on the investing side like most VCs. He specializes in immune system therapeutics and has co-founded multiple companies in areas like autoimmunity and oncology, including Surface Oncology, Q32 Bio, and Comanche Biopharma.
Focus Areas
Investment Stage
Investment Profile
David Grayzel is a Managing Director, Atlas Venture at Atlas Venture, based in Cambridge, MA.
David's investment focus spans Biotech, Digital Health, primarily investing at the Seed, Series A stages. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
Frequently Asked Questions
Who is David Grayzel?
David Grayzel is a Managing Director, Atlas Venture at Atlas Venture, based in Cambridge, MA. Their investment focus includes Biotech, Digital Health.
What does David Grayzel invest in?
David Grayzel focuses on investments in Biotech, Digital Health through Atlas Venture. These focus areas reflect their domain expertise and the types of startups they actively seek to back.
What firm is David Grayzel at?
David Grayzel is currently at Atlas Venture, headquartered in Cambridge, MA, serving as Managing Director, Atlas Venture.
Fund Operations Resources
Independent guides to the software and workflows venture investors and their firms use to run funds.
Best Fund Administration Software
Independent breakdown of fund administration platforms by fund size.
LP Reporting Software
Tools for capital account statements and investor updates.
Portfolio Monitoring Tools
How GPs track company performance across the portfolio.
VC CRM Software
Deal-flow and relationship management for investors.
Related tools and reading
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.